<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>Insys Therapeutics, Inc.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/lK1Y-TfftPKxubnKwwDePg==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2019, Insys Therapeutics, Inc.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Wed, 03 Jul 2019 10:00:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/07/03/1877750/0/en/FDA-Accepts-New-Drug-Application-for-INSYS-Therapeutics-Naloxone-Nasal-Spray-for-the-Emergency-Treatment-of-Known-or-Suspected-Opioid-Overdose.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/07/03/1877750/0/en/FDA-Accepts-New-Drug-Application-for-INSYS-Therapeutics-Naloxone-Nasal-Spray-for-the-Emergency-Treatment-of-Known-or-Suspected-Opioid-Overdose.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose</title>
      <description><![CDATA[<p align="justify">PHOENIX, July  03, 2019  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delivers 8mg naloxone dose.<br></p>]]></description>
      <pubDate>Wed, 03 Jul 2019 10:00 GMT</pubDate>
      <dc:identifier>1877750</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Wed, 03 Jul 2019 10:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/06/12/1867514/0/en/INSYS-Therapeutics-Inc-Receives-Court-Approval-of-First-Day-Motions.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/06/12/1867514/0/en/INSYS-Therapeutics-Inc-Receives-Court-Approval-of-First-Day-Motions.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions</title>
      <description><![CDATA[Operations to Continue in the Ordinary Course During Court-Supervised Process <pre>Operations to Continue in the Ordinary Course During Court-Supervised Process</pre>]]></description>
      <pubDate>Wed, 12 Jun 2019 12:00 GMT</pubDate>
      <dc:identifier>1867514</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Wed, 12 Jun 2019 12:01 GMT</dc:modified>
      <dc:subject>Bankruptcy</dc:subject>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/06/10/1866165/0/en/INSYS-Therapeutics-Initiates-Court-Supervised-Process-to-Facilitate-Asset-Sales-and-Address-Legacy-Liabilities.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/06/10/1866165/0/en/INSYS-Therapeutics-Initiates-Court-Supervised-Process-to-Facilitate-Asset-Sales-and-Address-Legacy-Liabilities.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities</title>
      <description><![CDATA[<p align="center"><em>Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code</em><br></p>]]></description>
      <pubDate>Mon, 10 Jun 2019 10:07 GMT</pubDate>
      <dc:identifier>1866165</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 10 Jun 2019 10:07 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/05/10/1822144/0/en/INSYS-Therapeutics-Reports-First-Quarter-2019-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/05/10/1822144/0/en/INSYS-Therapeutics-Reports-First-Quarter-2019-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Reports First Quarter 2019 Results</title>
      <description><![CDATA[<p align="center"><strong><em>Company Continues to Execute Against Pipeline-Focused Strategy</em></strong><br><strong><em>New Drug Application Submitted for Proprietary Naloxone Nasal Spray Formulation</em></strong><br><strong><em>Company Provides Liquidity Update</em></strong></p>]]></description>
      <pubDate>Fri, 10 May 2019 23:05 GMT</pubDate>
      <dc:identifier>1822144</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Fri, 10 May 2019 23:05 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/04/15/1803975/0/en/INSYS-Therapeutics-Implements-Leadership-Changes.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/04/15/1803975/0/en/INSYS-Therapeutics-Implements-Leadership-Changes.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Implements Leadership Changes</title>
      <description><![CDATA[Andrew G. Long Appointed Chief Executive Officer <pre>Andrew G. Long Appointed Chief Executive Officer</pre>]]></description>
      <pubDate>Mon, 15 Apr 2019 12:30 GMT</pubDate>
      <dc:identifier>1803975</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 15 Apr 2019 12:30 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/03/25/1759945/0/en/INSYS-Therapeutics-to-Present-Poster-of-Pharmacokinetic-Study-of-Naloxone-Novel-Nasal-Spray-at-The-College-on-Problems-of-Drug-Dependence-Annual-Scientific-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/03/25/1759945/0/en/INSYS-Therapeutics-to-Present-Poster-of-Pharmacokinetic-Study-of-Naloxone-Novel-Nasal-Spray-at-The-College-on-Problems-of-Drug-Dependence-Annual-Scientific-Meeting.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting</title>
      <description><![CDATA[<p align="left">PHOENIX, March  25, 2019  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time.<br></p>]]></description>
      <pubDate>Mon, 25 Mar 2019 10:00 GMT</pubDate>
      <dc:identifier>1759945</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 25 Mar 2019 10:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/03/07/1750160/0/en/INSYS-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2018-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/03/07/1750160/0/en/INSYS-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2018-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results</title>
      <description><![CDATA[Strategic Transformation Building Momentum with Two Planned NDAs in 2019 <pre>Strategic Transformation Building Momentum with Two Planned NDAs in 2019</pre>]]></description>
      <pubDate>Thu, 07 Mar 2019 21:15 GMT</pubDate>
      <dc:identifier>1750160</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Thu, 07 Mar 2019 21:15 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/03/06/1749186/0/en/INSYS-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2018-Results-on-March-7.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/03/06/1749186/0/en/INSYS-Therapeutics-to-Report-Fourth-Quarter-and-Full-Year-2018-Results-on-March-7.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7</title>
      <description><![CDATA[<p>PHOENIX, March  06, 2019  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, Mar. 7, after the U.S. financial markets close.<br></p>]]></description>
      <pubDate>Wed, 06 Mar 2019 21:15 GMT</pubDate>
      <dc:identifier>1749186</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Wed, 06 Mar 2019 21:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/02/25/1741354/0/en/INSYS-Therapeutics-Presented-Poster-of-Initial-Pharmacokinetic-Study-of-Epinephrine-Nasal-Spray-for-the-Emergency-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis-at-Am.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/02/25/1741354/0/en/INSYS-Therapeutics-Presented-Poster-of-Initial-Pharmacokinetic-Study-of-Epinephrine-Nasal-Spray-for-the-Emergency-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis-at-Am.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting</title>
      <description><![CDATA[<p align="justify">PHOENIX, Feb.  25, 2019  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, presented a poster of its initial pharmacokinetic (PK) study of comparative bioavailability of epinephrine nasal spray and EpiPen<sup>®</sup> in adults with seasonal allergies at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Francisco, California on Feb. 24, 2019.<br></p>]]></description>
      <pubDate>Mon, 25 Feb 2019 11:00 GMT</pubDate>
      <dc:identifier>1741354</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 25 Feb 2019 11:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/01/09/1682625/0/en/INSYS-Therapeutics-Announces-Results-of-Dose-Finding-PK-Study-for-Epinephrine-Nasal-Spray-for-Treatment-of-Anaphylaxis.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/01/09/1682625/0/en/INSYS-Therapeutics-Announces-Results-of-Dose-Finding-PK-Study-for-Epinephrine-Nasal-Spray-for-Treatment-of-Anaphylaxis.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis</title>
      <description><![CDATA[Company’s Proprietary Formulation Continues to Show Promise as Potential Alternative to Intramuscular Injection <pre>Company’s Proprietary Formulation Continues to Show Promise as Potential Alternative to Intramuscular Injection</pre>]]></description>
      <pubDate>Wed, 09 Jan 2019 11:00 GMT</pubDate>
      <dc:identifier>1682625</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Wed, 09 Jan 2019 11:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2019/01/03/1679962/0/en/INSYS-Therapeutics-to-Present-at-37th-Annual-J-P-Morgan-Healthcare-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2019/01/03/1679962/0/en/INSYS-Therapeutics-to-Present-at-37th-Annual-J-P-Morgan-Healthcare-Conference.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference </title>
      <description><![CDATA[<p>PHOENIX, Jan.  03, 2019  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari, president and chief executive officer, and Andy Long, chief financial officer, will present at the J.P. Morgan Healthcare Conference as follows:<br></p>]]></description>
      <pubDate>Thu, 03 Jan 2019 11:00 GMT</pubDate>
      <dc:identifier>1679962</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Thu, 03 Jan 2019 11:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/18/1668539/0/en/INSYS-Therapeutics-Announces-Participation-at-FDA-Advisory-Committee-Meeting-Addressing-the-Co-Prescribing-of-Naloxone.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/12/18/1668539/0/en/INSYS-Therapeutics-Announces-Participation-at-FDA-Advisory-Committee-Meeting-Addressing-the-Co-Prescribing-of-Naloxone.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone</title>
      <description><![CDATA[<p align="left">PHOENIX, Dec.  18, 2018  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that Dr. Dean Mariano, senior director, clinical development and medical affairs at INSYS, presented during the first day of the U.S. Food and Drug Administration’s (FDA) Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee meeting being held Dec. 17 and 18, 2018.<br></p>]]></description>
      <pubDate>Tue, 18 Dec 2018 11:00 GMT</pubDate>
      <dc:identifier>1668539</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Tue, 18 Dec 2018 11:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/17/1667742/0/en/INSYS-Therapeutics-Provides-Update-on-Strategic-Alterative-Review-Process-and-Product-Pipeline-Spanning-Pharmaceutical-Cannabinoids-and-Spray-Technology.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/12/17/1667742/0/en/INSYS-Therapeutics-Provides-Update-on-Strategic-Alterative-Review-Process-and-Product-Pipeline-Spanning-Pharmaceutical-Cannabinoids-and-Spray-Technology.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology</title>
      <description><![CDATA[Transformational momentum building as Company plans to apply for two NDAs in 2019 <pre>Transformational momentum building as Company plans to apply for two NDAs in 2019</pre>]]></description>
      <pubDate>Mon, 17 Dec 2018 11:00 GMT</pubDate>
      <dc:identifier>1667742</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 17 Dec 2018 11:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/12/04/1661469/0/en/INSYS-Therapeutics-Presents-New-Clinical-Data-from-Long-Term-Safety-Study-of-CBD-Oral-Solution-in-Refractory-Pediatric-Epilepsy.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/12/04/1661469/0/en/INSYS-Therapeutics-Presents-New-Clinical-Data-from-Long-Term-Safety-Study-of-CBD-Oral-Solution-in-Refractory-Pediatric-Epilepsy.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Presents New Clinical Data from Long-Term  Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy</title>
      <description><![CDATA[<p align="left">PHOENIX, Dec.  04, 2018  (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, was generally well-tolerated—even at high doses—as an investigational treatment for refractory pediatric epilepsy, according to new clinical data from a long-term safety study presented yesterday at the American Epilepsy Society (AES) 2018 annual meeting.<br></p>]]></description>
      <pubDate>Tue, 04 Dec 2018 11:00 GMT</pubDate>
      <dc:identifier>1661469</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Tue, 04 Dec 2018 11:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/20/1654358/0/en/Clinical-Data-from-Long-Term-Safety-Study-of-Company-s-Pharmaceutical-CBD-in-Refractory-Pediatric-Epilepsy-To-Be-Presented-at-American-Epilepsy-Society-Meeting.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/11/20/1654358/0/en/Clinical-Data-from-Long-Term-Safety-Study-of-Company-s-Pharmaceutical-CBD-in-Refractory-Pediatric-Epilepsy-To-Be-Presented-at-American-Epilepsy-Society-Meeting.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting</title>
      <description><![CDATA[<p align="justify">PHOENIX, Nov.  20, 2018  (GLOBE NEWSWIRE) -- Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory pediatric epilepsy will be presented on Dec. 3 at the 2018 American Epilepsy Society (AES) annual meeting in New Orleans. The product candidate evaluated in the study is from INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology.<br></p>]]></description>
      <pubDate>Tue, 20 Nov 2018 12:00 GMT</pubDate>
      <dc:identifier>1654358</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Tue, 20 Nov 2018 12:01 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:keyword>pharmaceuticals</dc:keyword>
      <dc:keyword>healthcare</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/05/1645547/0/en/INSYS-Therapeutics-Reports-Third-Quarter-2018-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/11/05/1645547/0/en/INSYS-Therapeutics-Reports-Third-Quarter-2018-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Reports Third Quarter 2018 Results</title>
      <description><![CDATA[<p align="left"><strong>Company’s Position as a Leader and Strategic Partner in Pharmaceutical Cannabinoids Strengthens with Involvement in Seven CBD Clinical Trials</strong><br></p>]]></description>
      <pubDate>Mon, 05 Nov 2018 21:16 GMT</pubDate>
      <dc:identifier>1645547</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 05 Nov 2018 21:16 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/05/1645540/0/en/INSYS-Therapeutics-to-Assess-Strategic-Alternatives-for-Opioid-Related-Assets.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/11/05/1645540/0/en/INSYS-Therapeutics-to-Assess-Strategic-Alternatives-for-Opioid-Related-Assets.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets</title>
      <description><![CDATA[<p align="left"><strong>Company Reiterates Focus on Pharmaceutical Cannabinoids and Spray Technology</strong></p>]]></description>
      <pubDate>Mon, 05 Nov 2018 21:15 GMT</pubDate>
      <dc:identifier>1645540</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 05 Nov 2018 21:15 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/11/01/1640890/0/en/INSYS-Therapeutics-Announces-Results-of-PK-Study-Assessing-Proprietary-Intranasal-Naloxone-Formulations-versus-Intramuscular-and-Intravenous-Naloxone-for-Opioid-Overdose.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/11/01/1640890/0/en/INSYS-Therapeutics-Announces-Results-of-PK-Study-Assessing-Proprietary-Intranasal-Naloxone-Formulations-versus-Intramuscular-and-Intravenous-Naloxone-for-Opioid-Overdose.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose</title>
      <description><![CDATA[<p align="left">PHOENIX, Nov.  01, 2018  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), today announced that a pharmacokinetic (PK) study (INS012-18-119) of its proprietary intranasal naloxone spray formulations for the treatment of opioid overdose showed a distinctive PK profile compared to the current standards of intramuscular (IM) and intravenous (IV) administration of naloxone.<br></p>]]></description>
      <pubDate>Thu, 01 Nov 2018 10:00 GMT</pubDate>
      <dc:identifier>1640890</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Thu, 01 Nov 2018 10:01 GMT</dc:modified>
      <media:content
        medium="image"
        type="image/jpeg"
        width="600"
        url="https://resource.globenewswire.com/Resource/Download/e3898b15-e29a-4769-ab49-1a42f0748610">
        <media:text
          type="html"><![CDATA[<p>
  <a href="https://www.globenewswire.com/news-release/2018/11/01/1640890/0/en/INSYS-Therapeutics-Announces-Results-of-PK-Study-Assessing-Proprietary-Intranasal-Naloxone-Formulations-versus-Intramuscular-and-Intravenous-Naloxone-for-Opioid-Overdose.html">
    <img src="https://resource.globenewswire.com/Resource/Download/e3898b15-e29a-4769-ab49-1a42f0748610" width="600" align="left" border="0" alt="Mean Unconjugated Naloxone Concentrations On Linear Scale" title="PK Profile" />
  </a>
</p><br clear="all" />]]></media:text>
        <media:credit
          role="publishing company">GlobeNewswire Inc.</media:credit>
      </media:content>
      <dc:subject>Product / Services Announcement</dc:subject>
      <dc:keyword>pharmaceuticals</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/10/22/1625059/0/en/INSYS-Therapeutics-to-Report-Third-Quarter-2018-Results-on-Nov-5.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/10/22/1625059/0/en/INSYS-Therapeutics-to-Report-Third-Quarter-2018-Results-on-Nov-5.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5</title>
      <description><![CDATA[<p align="justify">PHOENIX, Oct.  22, 2018  (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its third quarter 2018 financial results on Monday, Nov. 5, after the U.S. financial markets close.<br></p>]]></description>
      <pubDate>Mon, 22 Oct 2018 21:00 GMT</pubDate>
      <dc:identifier>1625059</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Mon, 22 Oct 2018 21:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2018/10/12/1620433/0/en/INSYS-Therapeutics-and-UC-San-Diego-s-Center-for-Medicinal-Cannabis-Research-Add-Anxiety-in-Anorexia-Nervosa-to-Series-of-Collaborative-Cannabidiol-CBD-Studies.html</guid>
      <link>https://www.globenewswire.com/news-release/2018/10/12/1620433/0/en/INSYS-Therapeutics-and-UC-San-Diego-s-Center-for-Medicinal-Cannabis-Research-Add-Anxiety-in-Anorexia-Nervosa-to-Series-of-Collaborative-Cannabidiol-CBD-Studies.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">Nasdaq:INSY</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45824V2097</category>
      <title>INSYS Therapeutics and UC San Diego’s Center for  Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to  Series of Collaborative Cannabidiol (CBD) Studies</title>
      <description><![CDATA[To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution <pre>To advance the medical science of pharmaceutical cannabinoids, pioneering company has now committed to supporting seven clinical trials of its proprietary CBD oral solution</pre>]]></description>
      <pubDate>Fri, 12 Oct 2018 10:00 GMT</pubDate>
      <dc:identifier>1620433</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>INSYS Therapeutics, Inc.</dc:contributor>
      <dc:modified>Fri, 12 Oct 2018 10:00 GMT</dc:modified>
      <dc:subject>Company Announcement</dc:subject>
      <dc:keyword>healthcare</dc:keyword>
      <dc:keyword>pharmaceuticals</dc:keyword>
    </item>
  </channel>
</rss>